Literature DB >> 10535347

The significance of an 'insufficient' Pipelle sample in the investigation of post-menopausal bleeding.

T Farrell1, N Jones, P Owen, A Baird.   

Abstract

BACKGROUND: Out-patient endometrial sampling is a commonly performed procedure in the investigation of post-menopausal bleeding. We hypothesized that an 'insufficient' Pipelle sample reliably reflected the absence of serious endometrial pathology. METHODS AND
RESULTS: A review of 141 consecutive cases reported as 'insufficient' for diagnostic purposes revealed 29 (20%) cases to have uterine pathology after secondary investigation. These included two cases of endometrial carcinoma and two other cases of uterine malignancy.
CONCLUSION: These results do not support the initial hypothesis and suggest that in women presenting with post-menopausal bleeding, an 'insufficient' sample is an indication for further investigation.

Entities:  

Mesh:

Year:  1999        PMID: 10535347

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  4 in total

1.  Results of a questionnaire regarding criteria for adequacy of endometrial biopsies.

Authors:  V Phillips; W G McCluggage
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

2.  Abnormal uterine bleeding: an evaluation endometrial biopsy, vaginal ultrasound and outpatient hysteroscopy.

Authors:  D C Hunter; N McClure
Journal:  Ulster Med J       Date:  2001-05

3.  Long-term risk of endometrial cancer following postmenopausal bleeding and reassuring endometrial biopsy.

Authors:  Nicole C M Visser; Ellen M Sparidaens; Jan-Willem van den Brink; Maria C Breijer; Erik A Boss; Sebastiaan Veersema; Albert G Siebers; Johan Bulten; Johanna M A Pijnenborg; Ruud L M Bekkers
Journal:  Acta Obstet Gynecol Scand       Date:  2016-10-14       Impact factor: 3.636

Review 4.  Preoperative assessment of endometrial cancer.

Authors:  Péter Török; Zoárd Krasznai; Szabolcs Molnár; Rudolf Lampé; Attila Jakab
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.